Navigation Links
SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
Date:4/16/2008

DUBLIN, Calif., April 16 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that that it has identified a lead PIM kinase inhibitor, SGI-1776, that causes tumor regression in acute myologenous leukemia (AML) xenograft models (Abstract No. 4083).

In an oral presentation entitled, "A potent small molecule PIM kinase inhibitor with activity in cell lines from hematological and solid malignancies," Dr. Steven Warner detailed how scientists used SuperGen's CLIMB(TM) technology to build a model that allowed for the creation of small molecule PIM kinase inhibitors. SGI-1776 was identified as a potent and selective inhibitor of the PIM kinases, inducing apoptosis and cell cycle arrest, thereby causing a reduction in phospho-BAD levels and enhancement of mTOR inhibition in vitro. Most notably, SGI-1776 induced significant tumor regression in MV-4-11 (prostate cancer) and MOLM-13 (AML) xenograft models.

"We are encouraged by these promising data. Our PIM kinase inhibitor, SGI-1776, may prove to be a treatment for AML, and other malignancies that over express PIM kinase," said Dr. James Manuso, SuperGen's President and Chief Executive Officer. "The data also provide support for the use of our CLIMB(TM) technology to identify and rapidly advance candidates into the clinic. We plan to initiate Phase 1 clinical trials with SGI-1776 in solid tumors and leukemias later this year. SGI-1776 may become the first drug in this class of inhibitors to enter the clinic."

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns

SuperGen, Inc.

SVP, Corporate Communications & Business Development

Tel: (925) 560-0100

E-mail: tenns@supergen.com

Mary M. Vegh

SuperGen, Inc.

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Show SuperGens MP-470 is Safe in Humans
2. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
3. SuperGens MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib
4. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
5. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
6. Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization
7. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
8. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
9. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
10. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
11. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ ... Tissue Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - ... reach USD 779.8 Million by 2021 from USD 414.6 Million in ... of 2016 to 2021. Continue Reading ... ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 According ... by Product Type and by Application - Global Opportunity Analysis and Industry Forecast, ... 2015, and is expected to reach $5,255 million by 2022, growing at a ... in 2015 with more than four-fifths share. Continue ... ...
(Date:12/5/2016)... and PUNE, India , December ... report by Allied Market Research, titled, "Global Cancer Biomarkers Market ... revenue of cancer biomarkers market is projected to reach $15,737 ... CAGR of 13.3% from 2016 to 2022. Omic technologies segment ... 2015 and is expected to maintain its dominance during the ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... ... For many years, Andrew G. Zubinas has accumulated over 130 hardcover ... Lithuanian language and its poetry inspired him in writing “ Forest Lungs ... aspects of a living, breathing forest where nothing ever stays the same. His subjects ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... announced today that nominations will be accepted from December 5, 2016 through ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ... global lifestyle design firm kathy ireland® Worldwide for five additional years, announced by ... into an exclusive licensing agreement three years ago to design and develop the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive ... of L-Citrulline and glutathione to enhance production of nitric oxide (NO). , NitroGenesis ... shown to produce NO twice as effectively and sustains NO blood levels twice ...
(Date:12/5/2016)... ... December 05, 2016 , ... ICA, ... alerting technology to Central Illinois Health Information Exchange (CIHIE) using its Smart ... as the sole sub-recipient participating with the Illinois Health Information Exchange Authority ...
Breaking Medicine News(10 mins):